Related Experiment Video

Updated: Apr 25, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K

Patients at high risk for recurrence need radiotherapy

Eli Glatstein, John P Plastaras

    Clinical Advances in Hematology & Oncology : H&O
    |August 20, 2014
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Stereotactic Radiosurgery for Gynecologic Cancer
    10:35

    Stereotactic Radiosurgery for Gynecologic Cancer

    Published on: April 17, 2012

    22.0K
    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    9.2K

    Related Experiment Videos

    Last Updated: Apr 25, 2026

    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
    08:34

    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

    Published on: February 6, 2019

    20.6K
    Stereotactic Radiosurgery for Gynecologic Cancer
    10:35

    Stereotactic Radiosurgery for Gynecologic Cancer

    Published on: April 17, 2012

    22.0K
    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    9.2K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    2.6K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    2.6K
    Cancer Therapies02:49

    Cancer Therapies

    8.1K
    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    8.1K

    Articles linked to this work by shared authors, journal, and citation graph.

    Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis.

    Practical radiation oncology·2026

    Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

    Blood advances·2026

    Consensus radiation therapy organ at risk constraints for NCTN trials in hematologic malignancies.

    Journal of the National Cancer Institute·2026

    Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma.

    Clinical lymphoma, myeloma & leukemia·2026

    Reirradiation clinical practice in gastrointestinal abdominal malignancies: an international reirradiation collaborative group (ReCOG) systematic review.

    Clinical and translational radiation oncology·2025

    Real-time dosimetry using scintillator technology in external beam radiation therapy (EBRT).

    Proceedings of SPIE--the International Society for Optical Engineering·2025

    Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations.

    Clinical advances in hematology & oncology : H&O·2026

    Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

    Clinical advances in hematology & oncology : H&O·2026

    Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer.

    Clinical advances in hematology & oncology : H&O·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us